EMA Authorised: Andembry (garadacimab) — CSL Behring GmbH

View source ↗

Summary

The EMA authorized Andembry (garadacimab) for hereditary angioedema. CSL Behring GmbH is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ANDEMBRY (garadacimab)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: CSL Behring GmbH. Decision date: 10/02/2025